Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target reflects the cloudy Eylea franchise but said the capital return to shareholders is a positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron upgraded to Outperform from Market Perform at Leerink
- Regeneron Reports Strong 2024 Earnings and Strategic Initiatives
- Regeneron Reports Strong Growth and Promising Pipeline
- China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz
- MAIA Biotechnology announces updated data from THIO-101 trial